Global head of Sandoz earns spot on ‘Fortune’ list
HOLZKIRCHEN, Germany — Jeff George, the global head of Sandoz, was ranked No. 9 on Fortune magazine’s annual top “40 under 40” list, a selection of the top 40 young business leaders from a variety of industries.
George, who has served as head of Sandoz since 2008, has led the drug maker to achieve double-digit revenue growth and make significant strides with respect to its differentiated products strategy, particularly in the field of biosimilars, Sandoz said.
Click here to view the full list.
Novo Nordisk partners with Paula Deen in new diabetes initiative
PRINCETON, N.J. — Danish drug maker Novo Nordisk is partnering with cooking show host Paula Deen to launch a campaign to help adults find ways to manage challenges associated with Type 2 diabetes, the company said Tuesday.
Deen and her sons, Bobby and Jamie, star in a series of videos as part of the Diabetes in a New Light initiative, in which Deen is sharing her personal diabetes story for the first time.
"I was determined to share my positive approach and not let diabetes stand in the way of enjoying my life," Deen said. "I’m excited to team up with Novo Nordisk on this initiative to show others that managing diabetes does not have to stop you from enjoying the things you love."
The initiative will include resources, such as recipes for dishes that are safe for people with diabetes but don’t compromise taste, instructions on incorporating physical activity into everyday life, managing stress and working with healthcare providers.
FDA issues alert about sharing of insulin pens
SILVER SPRING, Md. — The Food and Drug Administration’s latest message to consumers and healthcare professionals seems like a no-brainer: "Insulin pens are not for sharing."
But the agency said it knew of two undisclosed hospitals that it said had reused the cartridge components of insulin pens in administering insulin to more than 2,000 patients, though the hospitals reportedly changed the pens themselves.
This may have put the patients at risk for contracting HIV, hepatitis and other blood-borne viruses, the agency said, citing an alert it issued in March 2009. The FDA said the hospitals have been contacting the patients involved and offering to test them for hepatitis and HIV; some of the patients reportedly have tested positive for hepatitis C, though whether they contracted it from the pens remains unclear.